Evidence map›Paper›PMID 40504108›Full record

ArticleCell proliferation2026

Tryptophan Suppresses FTH1-Driven Ferritinophagy, a Key Correlate of Prognosis in Hepatocellular Carcinoma.

Xinxiang Cheng, Xin Ge, Chi Zhang, Xingye Yang, Zhengxin Yu, Min Zhang, Wen Cao, Qingtao Ni, Yang Liu, Songbing He and 1 more

Abstract read
In one paragraph

Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression.JHEP reports : innovation in hepatology · 2026
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinxiang ChengDepartment of General Surgery, Wuxi No. 2 Chinese Medcine Hospital, Wuxi, China.
Xin GeDepartment of Emergency Medicine, Wuxi No. 2 Chinese Medcine Hospital, Wuxi, China.
Chi ZhangDepartment of Hepatobiliary Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Xingye YangDepartment of Hepatobiliary Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Zhengxin YuDepartment of General Surgery, Wuxi No. 2 Chinese Medcine Hospital, Wuxi, China.
Min ZhangDepartment of General Surgery, Wuxi No. 2 Chinese Medcine Hospital, Wuxi, China.
Wen CaoDepartment of Liver Disease, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Qingtao NiDepartment of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.ORCID https://orcid.org/0000-0003-0263-5993
Yang LiuDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Songbing HeDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Cancer Institute, Suzhou Medical College, Soochow University, Suzhou Biomedical Industry Innovation Center & National Center of Technology Innovation for Biopharmaceuticals, Suzhou, China.
Yin YuanDepartment of Hepatobiliary Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.

Funding

China Postdoctoral Science Foundation 2024M762336General project of Health Commission of Jiangsu Province H2023132Key research project of Taizhou School of Clinical Medicine, Nanjing Medical University TZKY20230306National Natural Science Foundation of China 82372746Project of Health Personnel Training in Suzhou GSWS2020073Project of science and technology development plan in Suzhou SKY2022190Provincial-level talent program for National center of technology innovation for bio pharmaceuticals NCTIB2024JS0101Research Start-up Fund project of the affiliated Taizhou People's Hospital of Nanjing Medical University QDJJ202103Science and Technology Plan Project of Taizhou TS202306Suzhou Basic Research Pilot Project SSD2024047
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a lethal malignancy with limited therapeutic options. Ferritinophagy, an autophagy-dependent process regulating iron metabolism, has emerged as a key contributor to ferroptosis and tumour progression. This study hypothesised that the ferritinophagy-related gene FTH1 drives HCC pathogenesis by modulating tryptophan metabolism and reactive oxygen species (ROS)-dependent ferroptosis. To test this, we first analysed TCGA data to identify prognostic ferritinophagy genes, revealing FTH1 as a critical risk factor. Functional experiments using FTH1-knockdown/-overexpressing HCC cell lines and xenograft models demonstrated that FTH1 enhances proliferation, migration, and tumour growth by upregulating CYP1A1/CYP1A2 in the tryptophan pathway, thereby increasing the synthesis of 6-hydroxymelatonin (6-HMT). Mechanistically, 6-HMT suppressed ROS and ferroptosis by inhibiting cytochrome P450 oxidoreductase (POR). Concurrently, intracellular tryptophan levels were found to inhibit NCOA4-mediated selective autophagy of FTH1, stabilising FTH1 levels and promoting tumour survival. Collectively, our findings establish FTH1 as a central regulator of ferritinophagy in HCC and reveal its dual role in linking tryptophan metabolism to redox homeostasis. This result provides a hint of how FTH1 influences HCC pathogenesis and positions the tryptophan metabolism pathway as a promising therapeutic target.

Indexed as

Alcohol OxidoreductasesAutophagyCarcinoma, HepatocellularFerritinsLiver NeoplasmsTryptophanAnimalsCell Line, TumorCell ProliferationFerroptosisHumansMiceMice, NudeOxidoreductasesPrognosisReactive Oxygen SpeciesAlcohol OxidoreductasesFerritinsFTH1 protein, humanOxidoreductasesReactive Oxygen SpeciesTryptophanautophagyferritinophagyFTH1hepatocellular carcinomareactive oxygen speciestryptophan

Identifiers

PMID40504108
PMCPMC12774622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.